Parenteral Formulation for New Class (DNA Minor Groove Binder) Anti-Infective

新类（DNA小沟粘合剂）抗感染注射剂

• 批准号: 710161
• 金额: $ 12.74万
• 依托单位: MGB BIOPHARMA LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710161
• 关键词: Parenteral; Formulation; New; Class; DNA

MGB's preclinical candidate drug MGB BP3 is a potent anti-infective compound with highpotency against Gram +ve bacteria, including life threatening highly resistant strains such asMRSA. The compound shows unusual physicochemical characteristics which makesolubilisation very challenging As a result, MGB Biopharma has been forced to adopt an oralformulation to treat just a subset of bacterial infections - that of Clostridium difficile. Theformulation for that indication was recently successfully shown to be superior to the goldstandard drug (vancomycin) in the classic Hamster model. To be able to utilise this new classof drug against the most troublesome infectious diseases we need to extend the formulationsin development to be able to successfully produce a reproducible and stable product capableof being given by the intravenous route to patients who are at risk of death due to resistantbacterial and other infections.

MGB的临床前候选药物MGB BP 3是一种有效的抗感染化合物，对革兰氏阳性菌具有高效力，包括威胁生命的高耐药菌株，如MRSA。该化合物显示出不寻常的物理化学特性，这使得溶解非常具有挑战性，因此，MGB Bioburma被迫采用口服制剂来治疗细菌感染的一个子集-艰难梭菌。该制剂最近在经典的顺铂模型中成功地显示出上级金标准药物（万古霉素）。为了能够利用这类新药对抗最棘手的感染性疾病，我们需要扩展开发中的配方，以便能够成功地生产出一种可重复的和稳定的产品，能够通过静脉途径给予因耐药细菌和其他感染而有死亡风险的患者。